Methotrexate for ectopic pregnancy: when and how

dc.contributor.authorCecchino, Gustavo Nardini [UNIFESP]
dc.contributor.authorAraujo Junior, Edward [UNIFESP]
dc.contributor.authorElito Junior, Julio [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:37:47Z
dc.date.available2016-01-24T14:37:47Z
dc.date.issued2014-09-01
dc.description.abstractEctopic pregnancy is the leading cause of maternal death in the first trimester of pregnancy. the dosage of beta fraction of human chorionic gonadotropin (beta-hCG) and improvement of the transvaginal ultrasound allowed an earlier diagnosis and a conservative management. Currently, the use of systemic methotrexate (MTX) proved to be a great alternative with similar success rates and completely non-invasive.We searched for the most relevant articles on the use of MTX in ectopic pregnancy published between 2003 and 2013 in high-impact journals. We performed a strategic search at the Centre for Reviews and Dissemination (CRD), Database of Abstracts of Reviews of Effects (DARE), National Institute for Health Research (NHS), International Prospective Register of Systematic Reviews (PROSPERO), the Cochrane Database of Systematic Reviews (CDSR) and Medical Literature Analysis and Retrieval System Online (MEDLINE) according to the descriptors pregnancy, ectopic and methotrexate, alone or combined.Thus, we based this review on 32 studies that were classified following the grades of recommendation and levels of evidence proposed by the Oxford Centre for Evidence-Based Medicine. Additionally, selected papers were used. Scientific evidence points to a growing trend in the choice of conservative treatment for ectopic pregnancies, whereas expectant management still lacks studies for definitive conclusions. Indeed, the well-established protocols which exhibit a greater number of studies are still based on the single-dose treatment.Considering MTX, it proved to be more effective in cases of low titers of beta-hCG and masses with a small diameter, although there is still no uniformity of these parameters. the choice largely depends on the experience of the medical team and ultimately, on the woman's reproductive desire.en
dc.description.affiliationFed Univ São Paulo UNIFESP, Dept Obstet, BR-05303000 São Paulo, Brazil
dc.description.affiliationUnifespFed Univ São Paulo UNIFESP, Dept Obstet, BR-05303000 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent417-423
dc.identifierhttp://dx.doi.org/10.1007/s00404-014-3266-9
dc.identifier.citationArchives of Gynecology and Obstetrics. Heidelberg: Springer Heidelberg, v. 290, n. 3, p. 417-423, 2014.
dc.identifier.doi10.1007/s00404-014-3266-9
dc.identifier.issn0932-0067
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/38139
dc.identifier.wosWOS:000340518300008
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofArchives of Gynecology and Obstetrics
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectEctopic pregnancyen
dc.subjectMethotrexateen
dc.subjectTherapeuticen
dc.subjectReproductive healthen
dc.titleMethotrexate for ectopic pregnancy: when and howen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções